NEW YORK, USA – July 16, 2019 – Creative Biolabs, a global leader in recombinant antibody engineering, offers antibody-enzyme conjugates for directed enzyme prodrug therapy (ADEPT) systems combined with various pro-drugs to achieve selective tumor cell elimination.
Considering the limited efficacy of cytotoxic chemotherapy, the action of cytotoxic substances to cancer sites are supposed to be confined for reducing systemic toxicity and increasing drug efficacy. Therefore, the antibody-enzyme conjugates endowed with cancer-selectivity by targeting to tumor cells using specific antibodies are regarded as robust tools to internalize the toxic enzyme into the tumor cell and launch cell-death processes.
As an “indirect targeting method”, ADEPT developed by scientists in Creative Biolabs produces and retains the cytotoxic substances exclusively at the cancer sites, creating high cytotoxic agent concentrations directly inside or around a tumor cell and decreasing the collateral toxicity related to normal tissue exposure.
For antibody discovery service of antibody enzyme conjugate, Creative Biolabs offers scFV and VHH, the most commonly used antibody forms in the ADEPT research area, which have been widely used in disease diagnosis or therapeutic treatment and cancer therapy. Besides, scFvs to semi protein, gPA33 antigen in colon cancers, CD20, and camelid VHH to carcinoembryonic antigen (CEA) are also provided for combination with different enzymes and prodrugs to treat diseases.
During the process of ADEPT development, a high-quality linker is capable of facilitating the conjugation of enzyme to antibodies and dictating the release mechanism. SATA and SMPB are the two typical cross-linkers offered in Creative Biolabs. The SATA (N-succinimidyl S-acetylthioacetate) adds sulfhydryl groups to proteins and other amine-containing molecules in a protected form. It has an N-hydroxysuccinimide (NHS) ester that forms a stable, covalent amide bond with primary amines and releases NHS as a by-product. SMPB and its water-soluble analog Sulfo-SMPB contain N-hydroxysuccinimide (NHS) ester and maleimide groups that allow covalent conjugation of amine- and sulfhydryl-containing molecules. NHS esters interact with primary amines at pH 7-9 to form amide bonds, while maleimides react with sulfhydryl groups at pH 6.5-7.5 to form stable thioether bonds.
“We offer a wide range of mAbs with high affinity and high specificity. Our seasoned scientists are skilled in designing a successful ADEPT project with comprehensive strategies. Based on the advanced technology platforms, we can guarantee global clients high-quality and cost-effective antibody conjugation service”, said by the scientist in Creative Biolabs.
Besides ADEPT services, Creative Biolabs is also committed to one-stop antibody drug conjugates services. More information can be reached at https://www.creative-biolabs.com/adc.
With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States